Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
Sponsor: Pacira Pharmaceuticals, Inc
Summary
This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).
Official title: A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery
Key Details
Gender
All
Age Range
0 Years - 6 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-03-29
Completion Date
2027-01
Last Updated
2025-12-29
Healthy Volunteers
No
Conditions
Interventions
EXPAREL
A single dose of EXPAREL Injectable Product via LIA
bupivacaine
A single dose of 0.25% bupivacaine via LIA
Locations (5)
Indiana University Health, Riley Hospital For Children
Indianapolis, Indiana, United States
St. Louis Children's Hospital (SLCH)
St Louis, Missouri, United States
Duke University Health System
Durham, North Carolina, United States
University of Oklahoma (OU) - Medical Center - The Children's Hospital
Oklahoma City, Oklahoma, United States
The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School
Houston, Texas, United States